Sam Raha Elevated to CEO at Myriad Genetics: Ushering in a New Era of Leadership

Myriad Genetics Inc. has officially named Sam Raha as its new President and Chief Executive Officer, marking a significant milestone in the company’s leadership evolution. Effective since April 30, 2025, Sam Raha has transitioned from his role as Chief Operating Officer to assume the helm of the diagnostics and genomics powerhouse. This strategic appointment underscores the company’s confidence in Raha’s vision and proven ability to drive operational excellence and sustainable growth in an increasingly competitive industry.

Leadership Transition: Sam Raha Steps Into the Top Role

The announcement comes as Paul Diaz, the company’s outgoing CEO, steps aside to pursue new opportunities with Cressey & Company, joining as a Managing Partner in the private equity sector. Rather than a complete departure, Diaz will continue to contribute to Myriad’s future, serving as a consultant to Sam Raha and the Board of Directors for an additional year. This structured transition reflects careful succession planning and ensures continuity during the leadership changeover.

S. Louise Phanstiel, Chair of Myriad’s Board of Directors, expressed strong support for the appointment, noting that Sam Raha has been instrumental in shaping the company’s long-term growth strategy since joining in December 2023. “His deep background in the diagnostics industry and demonstrated leadership throughout his career are crucial to advancing our mission of improving health and well-being for all while creating sustained value for our shareholders,” Phanstiel stated, highlighting the board’s confidence in the appointment.

Strengthening the Management Pipeline

Concurrent with Sam Raha’s elevation to CEO, Mark Verratti has been promoted to Chief Operating Officer, stepping into the role vacated by Raha. Verratti, previously serving as Chief Commercial Officer, brings valuable commercial and operational expertise to this expanded position. The company has already initiated a search for a successor to the Chief Commercial Officer role, ensuring no gaps in the leadership structure.

Sam Raha’s Industry Expertise and Vision

Sam Raha brings substantial credentials to his new position. Before joining Myriad, he served as President of Agilent’s Diagnostics and Genomics Group, where he oversaw comprehensive strategy, business development, and financial performance. His extensive experience navigating the diagnostics sector positions him well to lead Myriad through its next growth phase, leveraging deep industry knowledge to identify new opportunities and drive innovation across the company’s portfolio of diagnostic solutions.